.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,113,878

« Back to Dashboard

Details for Patent: 6,113,878

Title: Technetium-99m labeled peptides for imaging
Abstract:This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to peptides, methods and kits for making such peptides, and methods for using such peptides to image sites in a mammalian body labeled with technetium-99m (Tc-99m) via Tc-99m binding moieties. In particular, the peptide reagents of the invention are covalently linked to a polyvalent linker moiety, so that the polyvalent linker moiety is covalently linked to a multiplicity of the specific-binding peptides, and the Tc-99m binding moieties are covalently linked to a plurality of the specific-binding peptides, the polyvalent linker moiety, or to both the specific-binding peptides and the polyvalent linker moiety.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Jun 06, 1995
Application Number:08/467,567
Claims:1. A radiolabeled complex comprising:

a) technetium-99m; and

b) a reagent comprising:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids,

ii) a polyvalent linker covalently linked to each peptide, and

iii) a technetium-99m binding moiety covalently linked to a specific site on each peptide.

2. A method for labeling a reagent by ligand exchange, wherein the reagent comprises:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids,

ii) a polyvalent linker covalently linked to each peeptide, and

iii) a technetium-99m binding moiety covalently linked to a specific site on each peptide;

the method comprising the step of combining the reagent with a prereduced technetium-99m complex.

3. A method for labeling a reagent comprising:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids,

ii) a polyvalent linker covalently linked to each peptide, and

iii) a technetium-99m binding moiety covalently linked to a specific site on each peptide;

the method comprising the step of reacting the reagent with technetium-99m in the presence of a reducing agent.

4. The method of claim 3, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

5. A radiolabeled complex comprising technetium-99m and a reagent selected from the group consisting of:

(acetyl-F.sub.D PRPG).sub.2 KGGGCamide,

(GPRVVERHQSA).sub.2 KC.sub.Acm GC.sub.Acm amide,

{(GPRP).sub.2 K}.sub.2 KC.sub.Acm GC.sub.Acm amide, ##STR8## (CC.sub.Acm GC.sub.Acm GGRGDS).sub.3 -TSEA, (GPRPC.sub.Acm GC.sub.Acm Camide).sub.3 -TSEA,

(Pic.SC.sub.Acm SYNRGDSTCamide).sub.3 -TSEA,

(RALVDTLKGGC.sub.Acm GC.sub.Acm Camide).sub.3 -TSEA,

(GRGDFC.sub.Acm GC.sub.Acm Camide).sub.3 -TSEA,

(Pic.GC.sub.Acm RALVDTLKFVTQAEGAKCamide).sub.3 -TSEA, and

(acetyl-SYNRGDTC.sub.Acm GC.sub.Acm Camide).sub.2 -DMAB.

6. A radiolabeled complex comprising:

a) technetium-99m; and

b) a reagent comprising:

(i) a polyvalent linker;

(ii) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids and being covalently linked to said linker, and

(iii) a technetium-99m binding moiety covalently linked to said linker.

7. A method for labeling a reagent by ligand exchange, wherein the reagent comprises:

(i) a polyvalent linker;

(ii) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids and being covalently linked to said linker; and

(iii) a technetium-99m binding moiety covalently linked to said linker;

the method comprising the step of combining the reagent with a prereduced technetium-99m complex.

8. A method for labeling a reagent comprising:

(i) a polyvalent linker;

(ii) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids and being covalently linked to said linker, and

(iii) a technetium-99m binding moiety covalently linked to said linker;

the method comprising the step of reacting the reagent with technetium-99m in the presence of a reducing agent.

9. A radiolabeled complex comprising:

a) technetium-99m; and

b) a reagent comprising:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids;

ii) a branched polyvalent linker covalently linked to a specific site on each peptide; and

iii) a technetium-99m binding moiety covalently linked to the linker.

10. A method for labeling a reagent by ligand exchange, wherein the reagent comprises:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids;

ii) a branched polyvalent linker covalently linked to a specific site on each peptide; and

iii) a technetium-99m binding moiety covalently linked to the linker,

the method comprising the step of combining the reagent with a prereduced technetium-99m complex.

11. A method for labeling a reagent comprising:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids;

ii) a branched polyvalent linker covalently linked to a specific site on each peptide;

iii) a technetium-99m binding moiety covalently linked to the linker,

the method comprising the step of reacting the reagent with technetium-99m in the presence of a reducing agent.

12. A radiolabeled complex comprising:

a) technetium-99m; and

b) a reagent comprising:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids;

ii) a technetium-99m binding moiety covalently linked to a specific site on each peptide; and

iii) a polyvalent linker covalently linked to each technetium-99m binding moiety.

13. A method for labeling a reagent by ligand exchange, wherein the reagent comprises:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids;

ii) a technetium-99m binding moiety covalently linked to a specific site on each peptide; and

iii) a polyvalent linker covalently linked to each technetium-99m binding moiety;

the method comprising the step of combining the reagent with a prereduced technetium-99m complex.

14. A method for labeling a reagent comprising:

i) a multiplicity of synthetically prepared, specific-binding peptides, each peptide having an amino acid sequence of 3 to 100 amino acids;

ii) a technetium-99m binding moiety covalently linked to a specific site on each peptide; and

iii) a polyvalent linker covalently linked to each technetium-99m binding moiety;

the method comprising the step of reacting the reagent with technetium-99m in the presence of a reducing agent.

15. A method of making a technetium-99m labeled peptide comprising the step of combining ##STR9## with technetium-99m in the presence of stannous ions.

16. A method of making a technetium-99m labeled peptide by ligand exchange comprising the step of combining ##STR10## with a prereduced technetium-99m complex.

17. The complex of any of claims 1, 6, 9 or 12, wherein the linker comprises at least two identical functional groups.

18. The complex of claim 17, wherein the functional groups are selected from the group consisting of primary amines, secondary amines, hydroxyl groups, carboxylic acid groups, and thiol-reactive groups.

19. A complex according to any of claims 1, 6, or 12, wherein the linkers form a covalently linked, branched polyvalent linking moiety.

20. The complex of any of claims 1, 6, 9, or 12, wherein the technetium-99m binding moiety is selected from the group consisting of:

wherein c(pgp).sup.S is a cysteine having a protected thiol group and (aa) is an amino acid;

a technetium-99m binding moiety comprising a single thiol having a formula

wherein

A.sup.1 is H, HOOC, H.sub.2 NOC, or --NHOC;

B.sup.1 is SH or NHR.sup.3 ;

X.sup.1 is H, methyl, SH or NHR.sup.3 ;

Z.sup.1 is H or methyl;

R.sup.1 and R.sup.2 are independently H or lower alkyl;

R.sup.3 is H, lower alkyl or --C.dbd.O;

n is 0, 1 or 2;

and where B.sup.1 is NHR.sup.3, X.sup.1 is SH, Z.sup.1 is H and n is 1 or 2;

where X.sup.1 is NHR.sup.3, B.sup.1 is SH, Z.sup.1 is H and n is 1 or 2;

where B.sup.1 is H, A.sup.1 is HOOC, H.sub.2 NOC, or --NHOC, X.sup.1 is SH, Z.sup.1 is H and n is 0 or 1;

where Z.sup.1 is methyl, X.sup.1 is methyl, A.sup.1 is HOOC, H.sub.2 NOC, or --NHOC, B.sup.1 is SH and n is 0;

and wherein the thiol moiety is in the reduced form; ##STR11## wherein X.sup.2 .dbd.H or a protecting group;

(amino acid).dbd.any amino acid; ##STR12## wherein X.sup.2 .dbd.H or a protecting group;

(amino acid).dbd.any amino acid; ##STR13## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

each (pgp).sup.S is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A.sup.2 =linear or cyclic lower alkyl, aryl, heterocyclyl, or a combination thereof;

and ##STR14## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A.sup.3 =linear or cyclic lower alkyl, aryl, heterocyclyl, or a combination thereof;

V.dbd.H or --CO-peptide;

R.sup.4 .dbd.H or peptide;

and wherein when V.dbd.H, R.sup.4 .dbd.peptide and when R.sup.4 .dbd.H, V.dbd.--CO-peptide.

21. The complex of any of claims 1, 6, 9, or 12,

wherein the technetium-99m binding moiety is selected from the group consisting of a protected thiol-containing moiety, a single thiol containing complexing moiety, a picolinic acid-based moiety, a picolylamine-containing moiety, and a bisamine bisthiol-containing moiety.

22. The complex of any of claims 1, 6, 9, or 12,

wherein the linker comprises an amino acid selected from the group consisting of lysine, homocysteine, ornithine, aspartic acid, and glutamic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc